The International Kidney Cancer Symposium (IKCS) 2022: North America

REVIEW UroToday

Viewing 1-20 of 47 articles

IKCS 2022: Genetics in Kidney Cancer: Systemic Therapy for VHL and HLRCC Associated Cancers

IKCS 2022: Who, What, When, Where, and Why of Genetics in Kidney Cancer: Considerations for the Genetics Consensus Statement

IKCS 2022: Somatic Testing Considerations

IKCS 2022: Using Proper Risk Stratification and How to do it Accurately

IKCS 2022: Clinical Outcomes with Nivolumab/Ipilimumab (Nivo/Ipi) with or Without CBM588 in Metastatic Renal Cell Carcinoma (mRCC): Long-Term Follow-up of a Randomized Phase Ib Clinical Trial

IKCS 2022: Genetic Ancestry and Molecular Correlations in Patients with Kidney Cancers

IKCS 2022: Delineating Clinical and Radiologic Features of Rare Kidney Cancer Genetic Syndromes

IKCS 2022: Evolving Concepts of Risk Stratification in Metastatic Renal Cell Carcinoma

IKCS 2022: CD200-mediated Immune Evasion in Clear Cell Renal Cell Carcinoma

IKCS 2022: Critical Assessment of Eligibility Criteria in Contemporary Renal Cell Carcinoma Trials Evaluating Systemic Therapy

IKCS 2022: The New Era of Clinical Trials: Meeting Regulatory Requirements and Decreasing Barriers

IKCS 2022: Experiences With Patient Acceptance of Clinical Trials

IKCS 2022: Assessment of Clavien-Dindo Classification in Patients with Metastatic Clear Cell Renal Cell Carcinoma Who Received Perioperative Cabozantinib and Nivolumab on Cyto-KIK Clinical Trial

IKCS 2022: Choosing Endpoints and Designs of Future Trials: OS vs PFS and Comparator Cohorts

IKCS 2022: Daily Aspects of Side-Effect Management Logistics in Kidney Cancer Treatment

IKCS 2022: Depth of Response Associated with First-Line Immunotherapy-Based Combinations in Metastatic Clear Cell Renal Cell Carcinoma

IKCS 2022: Efficacy and Safety of Nivolumab plus Ipilimumab Versus Sunitinib for First-Line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma in the Phase 3 CheckMate 214 Trial with Extended 5-Year Minimum Follow-Up

IKCS 2022: Recurrent Genomic Alterations Driving Clear Cell Renal Cell Carcinoma Development

IKCS 2022: Quality of Life and Systemic Therapy for Renal Cell Carcinoma

IKCS 2022: Doublet or Triplet as First-Line Treatment in Kidney Cancer

1
2
3